SLU-PP-332 Research: What the Early Studies Have Investigated

What is SLU-PP-332?

What is SLU-PP-332? It is a synthetic small-molecule pan-agonist of the estrogen-related receptors — ERRα, ERRβ and ERRγ — with its highest potency at ERRα. It was developed as a pharmacological tool compound in the Burris laboratory at Saint Louis University and first characterised by Billon et al. (2023, ACS Chemical Biology). Despite how it is often marketed online, it is not a peptide: it has no amino-acid sequence but a defined small-molecule chemical structure of the hydrazone chemotype. It has been studied in animals under the research label of an “exercise mimetic” — a term describing the gene-expression program it induced in mice, not a promise of any effect in a person. Everything below describes what researchers examined in models, not effects in people.

Molecule properties

SLU-PP-332 is a synthetic small-molecule ERR agonist of the hydrazone chemotype. Structure–activity work by Okda et al. (2026, Int J Biol Macromol) mapped how the ring-A, ring-B and hydrazone-linker regions of the scaffold contribute to ERR potency and selectivity. It is worth stating the distinction plainly because it is so often confused online: unlike a peptide, SLU-PP-332 has no chain of amino acids — it is a single defined chemical structure. One pharmacology fact recorded in the rodent literature is that the parent compound was not orally bioavailable in those studies and was delivered by injection in the animal models; that limitation is cited as the motivation for a later orally active analog, SLU-PP-915 (Billon et al., 2026). In research catalogues it is supplied as a reference standard for laboratory use. These are molecule and pharmacology facts only — no handling, reconstitution or dosing guidance is given here.

What “ERR agonist” means (mechanism researchers examined)

The SLU-PP-332 mechanism question is, at heart, a question about the estrogen-related receptors it activates. Each direction below is framed as what researchers examined in cells and rodents:

• Estrogen-related receptors as metabolic transcription factors — ERRα, ERRβ and ERRγ are orphan nuclear receptors that, working with the coactivator PGC-1α, are described in review literature (Estrogen-Related Receptor Signaling in Skeletal Muscle Fitness, 2024) as regulators of mitochondrial biogenesis, oxidative phosphorylation, fatty-acid oxidation and the TCA cycle in skeletal muscle. SLU-PP-332 is a synthetic ligand that activates this axis pharmacologically.
• ERRα-dependent “acute aerobic exercise” gene program — Billon et al. (2023, ACS Chem Biol, PMID 36988910) reported that in mouse skeletal muscle and in C2C12 muscle cells, SLU-PP-332 induced a transcriptional program resembling the acute response to aerobic exercise, and that this response was dependent on ERRα, being lost in ERRα-knockout models.
• Mitochondrial and oxidative-fibre observations in mice — the same work reported increases in type IIa oxidative muscle fibres and in OXPHOS-related protein levels, alongside changes in running capacity, in the treated mice.
• Whole-body metabolic observations in obese-mouse models — Billon et al. (2024, J Pharmacol Exp Ther, PMID 37739806) reported, in diet-induced-obese and genetically obese ob/ob mice, changes in energy expenditure and fatty-acid oxidation and reduced fat-mass gain.

Read honestly, these are research observations in mice and cells, describing what an ERR agonist does in those models — not effects demonstrated in humans. The section names a pathway examined in each bullet, not an effect a reader would experience.

Research models in the literature

The models are preclinical throughout. In vitro, the studies used cultured C2C12 myoblasts and myotubes and primary myocytes. In vivo, they used C57BL/6 mice for the exercise-capacity and gene-expression work, diet-induced-obese and genetically obese ob/ob mice for the metabolic-syndrome study, and ERRα-knockout mice to test whether the effects depended on that receptor. A 2026 follow-up (Billon et al., J Pharmacol Exp Ther, PMID 41421047) introduced the orally active analog SLU-PP-915 and compared it with SLU-PP-332 in mice. Separately, medicinal-chemistry optimisation of the SLU-PP-332 chemotype (Okda et al., 2026, Int J Biol Macromol, PMID 41850449) used reporter assays, myotube and cardiomyocyte transcriptional profiling and computational modelling.

It bears stating plainly, and more than once, that the entire body of evidence is preclinical — cell and rodent — very recent, dating from 2023 onward, and concentrated in essentially a single research group. There are no human or clinical trials of SLU-PP-332. Animal and in-vitro findings, however consistent within their own models, cannot establish outcomes in people; a gene-expression program induced in a mouse does not transfer to a reader. That is the honest scope of the current literature, and it is the reason this page reports what was investigated rather than drawing conclusions about human use.

SLU-PP-332 among metabolic research compounds

In one line: SLU-PP-332 belongs to the cluster of early metabolic and mitochondrial research compounds, where its distinguishing feature is that it is a receptor-level tool — a synthetic ERR agonist — rather than a peptide or a naturally occurring molecule. That places it in different mechanistic company from the metabolic peptides and small molecules studied for adjacent questions. The detail belongs on the sibling pages rather than here: for a related small-molecule metabolic research explainer, see 5-Amino-1MQ research; for the mitochondrial-derived peptide literature, see MOTS-c research; and for the NAD+ precursor research record, see NAD+ research. This page deliberately hands off rather than ranking or comparing compounds.

Research-grade sourcing and verification

For laboratory research use only, SLU-PP-332 is supplied as a small-molecule reference standard with a per-batch Certificate of Analysis reporting HPLC purity (%) and mass-spec identity confirmation — that is, confirmation of the identity and purity of a defined chemical structure. Check the exact batch on the self-serve verify tool, and see how to read a COA for what the certificate reports. This is identity and quality assurance for research use, not a statement about outcomes.

Frequently asked questions

Literature cited

1. Billon C, Sitaula S, Banerjee S, et al. “Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity.” ACS Chemical Biology. 2023;18(4):756–771. PMID 36988910 (DOI 10.1021/acschembio.2c00720).
2. Billon C, Schoepke E, Avdagic A, et al. “A Synthetic ERR Agonist Alleviates Metabolic Syndrome.” J Pharmacol Exp Ther. 2024;388(2):232–240. PMID 37739806 (DOI 10.1124/jpet.123.001733).
3. Billon C, Appourchaux K, Côté I, Burris TP. “An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity.” J Pharmacol Exp Ther. 2026;393(1):103787. PMID 41421047 (DOI 10.1016/j.jpet.2025.103787).
4. Okda HE, et al. “Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling.” Int J Biol Macromol. 2026;355:151450. PMID 41850449.
5. Review context: “Estrogen-Related Receptor Signaling in Skeletal Muscle Fitness.” PMC11168301, 2024.